XML 83 R73.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Commitments and Contingencies - Additional Information (Detail) € in Millions, $ in Millions, $ in Millions |  |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended |  |  |  |  |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 27, 2018 CAD ($) | Aug. 21, 2017 USD ($) | Jul. 15, 2015 USD ($) | Jun. 30, 2018 USD ($) | Nov. 30, 2017 USD ($) | Dec. 31, 2014 USD ($) | Sep. 30, 2013 USD ($) | Aug. 31, 2012 USD ($) | Dec. 31, 2010 USD ($) | Nov. 30, 2009 USD ($) | Aug. 31, 2008 USD ($) | Apr. 30, 2005 USD ($) | Mar. 31, 2015 CAD ($) | Jun. 30, 2018 USD ($) Lawsuit | Jun. 30, 2018 EUR (€) | Jun. 30, 2018 CAD ($) | Jun. 20, 2017 USD ($) | Dec. 31, 2016 USD ($) | May 31, 2015 USD ($) | Mar. 31, 2014 USD ($) | Nov. 30, 2013 USD ($) | Aug. 31, 2013 USD ($) | Jan. 31, 2009 USD ($) | Jul. 31, 2008 USD ($) | Feb. 28, 2005 USD ($)
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Damages assessment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 235.5 |  |  |  |  |  |  |  |
Sales |  |  |  |  |  |  |  |  |  |  |  |  | $ 94 |  |  |  |  |  |  |  |  |  |  |  |
Brand sales |  |  |  |  | $ 459.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Modafinil payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,200.0 |  |  |  |  |  |
Modafinil Euro sales | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 46.5 |  |  |  |  |  |  |  |  |  |
Annual sales at the time of settlement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 350.0 |  |
Annual sales of Effexor |  | $ 2,600.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of Lamictal |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,300.0 | $ 950.0
Annual sales of Niaspan |  |  |  |  |  |  | $ 1,100.0 |  |  |  |  | $ 416.0 |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of Lidoderm |  |  |  |  |  |  | $ 1,400.0 |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,200.0 |  |  |  |
Annual sales of Aggrenox |  |  | $ 455.0 |  |  |  |  |  |  |  | $ 340.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of Actos |  |  |  |  |  |  |  | $ 2,800.0 | $ 3,700.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of Acto plus |  |  |  |  |  |  |  | $ 430.0 | $ 500.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nexium settlement payment |  |  |  |  |  | $ 24.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of Namenda |  |  |  |  |  |  |  |  |  | $ 1,100.0 |  |  |  | $ 1,400.0 |  |  |  |  |  |  |  |  |  |  |
Annual sales of Intuniv |  |  |  |  |  | $ 327.0 |  |  |  |  |  |  |  |  |  |  |  | $ 335.0 |  |  |  |  |  |  |
Compensatory damages for the state of Illinois |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 90.0 |  |  |  |  |  |  |  |  |  |  |
Compensatory Damages And Penalties |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 12.4 |  |  |
Punitive Damages |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 17.9 |  |  |  |  |
Number of lawsuits filed | Lawsuit |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,000 |  |  |  |  |  |  |  |  |  |  |
Israel [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency payment |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 22.0 |  |  |  |  |  |  |  |  |  |  |
Statutory Penalties [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Damage claimed |  |  |  |  |  |  |  |  |  |  |  |  |  | 362.0 |  |  |  |  |  |  |  |  |  |  |
Statutory Penalties [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Damage claimed |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,200.0 |  |  |  |  |  |  |  |  |  |  |
Eosinophilic Esophagitis [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Damage claimed |  |  |  |  |  |  |  |  |  |  |  |  |  | 200.0 |  |  |  |  |  |  |  |  |  |  |
Eosinophilic Esophagitis [Member] | United States [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Damage claimed |  |  |  |  |  |  |  |  |  |  |  |  |  | 150.0 |  |  |  |  |  |  |  |  |  |  |
Eosinophilic Esophagitis [Member] | Europe [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Damage claimed |  |  |  |  |  |  |  |  |  |  |  |  |  | 50.0 |  |  |  |  |  |  |  |  |  |  |
Janssen and Millennium [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum damages payable |  |  |  | $ 159.0 |  |  |  |  |  |  |  |  |  | $ 159.0 |  | $ 200 |  |  |  |  |  |  |  |  |
Litigation settlement awarded from other party | $ 5 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AbbVie [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement awarded from other party |  |  |  | $ 448.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AndroGel Rate at 1% [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales at the time of settlement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 140.0 |  |
AndroGel Rate at 1.62% [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales at the time of settlement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,050.0 |  |

X
- Definition Annual sales at time of settlement. + References No definition available. + Details
Name: | teva_AnnualSalesAtTimeOfSettlement
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Annual sales of Acto plus. + References No definition available. + Details
Name: | teva_AnnualSalesOfActoplus
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual sales of Actos. + References No definition available. + Details
Name: | teva_AnnualSalesOfActos
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual sales of Aggrenox. + References No definition available. + Details
Name: | teva_AnnualSalesOfAggrenox
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual sales of effexor. + References No definition available. + Details
Name: | teva_AnnualSalesOfEffexor
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual sales of Intuniv. + References No definition available. + Details
Name: | teva_AnnualSalesOfIntuniv
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Annual sales of Lamictal. + References No definition available. + Details
Name: | teva_AnnualSalesOfLamictal
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Annual sales of Lidoderm. + References No definition available. + Details
Name: | teva_AnnualSalesOfLidoderm
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Annual sales of Namenda. + References No definition available. + Details
Name: | teva_AnnualSalesOfNamenda
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual sales of Niaspan. + References No definition available. + Details
Name: | teva_AnnualSalesOfNiaspan
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual Sales Of Velcade + References No definition available. + Details
Name: | teva_AnnualSalesOfVelcade
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Brand sales of palonosetron IV product. + References No definition available. + Details
Name: | teva_BrandSalesOfPalonosetronIvProduct
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Commitment And Contingencies [Line Items] + References No definition available. + Details
Name: | teva_CommitmentAndContingenciesLineItems
Namespace Prefix: | teva_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Compensatory damages and penalties. + References No definition available. + Details
Name: | teva_CompensatoryDamagesAndPenalties
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Compensatory damages for state of Illinois. + References No definition available. + Details
Name: | teva_CompensatoryDamagesForStateOfIllinois
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Damages assessment. + References No definition available. + Details
Name: | teva_DamagesAssessment
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Modafinil Euro sales. + References No definition available. + Details
Name: | teva_ModafinilEuroSales
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Modafinil payment. + References No definition available. + Details
Name: | teva_ModafinilPayment
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Nexium settlement payment. + References No definition available. + Details
Name: | teva_NexiumSettlementPayment
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number Of Lawsuits Filed + References No definition available. + Details
Name: | teva_NumberOfLawsuitsFiled
Namespace Prefix: | teva_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Punitive damages. + References No definition available. + Details
Name: | teva_PunitiveDamages
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount awarded from other party in judgment or settlement of litigation. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementAmountAwardedFromOtherParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of damages paid to the plaintiff in the legal matter. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyDamagesPaidValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The value (monetary amount) of the award the plaintiff seeks in the legal matter. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyDamagesSoughtValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Reflects the estimated amount of loss from the specified contingency as of the balance sheet date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 460 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=115931803&loc=d3e12021-110248 + Details
Name: | us-gaap_LossContingencyEstimateOfPossibleLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | srt_StatementGeographicalAxis=country_IL
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LossContingenciesByNatureOfContingencyAxis=teva_StatutoryPenaltiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LossContingenciesByNatureOfContingencyAxis=teva_EosinophilicEsophagitisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=teva_JanssenAndMillenniumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=teva_AbbVieMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_AndroGelRateAtOnePercentageMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_AndroGelRateAtOnePointSixTwoPercentageMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |